Premium
Back Cover: Rational Design of Selenadiazole Derivatives to Antagonize Hyperglycemia‐Induced Drug Resistance in Cancer Cells (Chem. Asian J. 3/2015)
Author(s) -
Liu Yuedan,
Luo Yi,
Li Xiaoling,
Zheng Wenjie,
Chen Tianfeng
Publication year - 2015
Publication title -
chemistry – an asian journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.18
H-Index - 106
eISSN - 1861-471X
pISSN - 1861-4728
DOI - 10.1002/asia.201590008
Subject(s) - ampk , mtorc1 , pi3k/akt/mtor pathway , pharmacology , reactive oxygen species , cancer , drug , cancer cell , chemistry , medicine , kinase , protein kinase a , biochemistry , signal transduction
Medicinal Chemistry Hyperglycemia could be one of the most important reasons accounting for the chemoresistance of cancer patients with diabetes to therapeutics. In their Full Paper on page 642 ff. , featured on the Back Cover, Xiaoling Li, Tianfeng Chen et al. report on the rational design of selenadiazole derivatives that could antagonize the drug resistance of HepG2 hepatocellular carcinoma cells to anticancer drugs under simulated diabetes conditions, through overproduction of reactive oxygen species (ROS), activation of adenosine monophosphate‐activated kinase (AMPK), and inhibition of mTOR Complex1 (mTORC1). This study may provide an effective strategy to design selenadiazole derivatives with the potency to overcome hyperglycemia‐induced drug resistance.